Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 213

1.

Predicting self-perceived antimuscarinic therapy effectiveness on overactive bladder symptoms using the Overactive Bladder 8-Question Awareness Tool.

Villacampa F, Ruiz MA, Errando C, Arlandis S, Arumí D, Lizarraga I, Rejas J.

Int Urogynecol J. 2013 Apr;24(4):573-81. doi: 10.1007/s00192-012-1921-x. Epub 2012 Oct 31.

PMID:
23111865
2.

Quality of life in patients with overactive bladder: validation and psychometric properties of the Spanish Overactive Bladder Questionnaire-short Form.

Arlandis S, Ruiz MA, Errando C, Villacampa F, Arumí D, Lizarraga I, Rejas J.

Clin Drug Investig. 2012 Aug 1;32(8):523-32. doi: 10.2165/11633760-000000000-00000.

PMID:
22741748
3.

Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.

Ginsberg D, Schneider T, Kelleher C, Van Kerrebroeck P, Swift S, Creanga D, Martire DL.

BJU Int. 2013 Aug;112(3):373-85. doi: 10.1111/bju.12174.

4.

A prospective observational study of the effects of treatment with extended-release tolterodine on health-related quality of life of patients suffering overactive bladder syndrome in Sweden.

Peeker R, Samsioe G, Kowalski J, Andersson AS, Bergqvist A.

Scand J Urol Nephrol. 2010 Apr;44(3):138-46. doi: 10.3109/00365591003709468.

PMID:
20367449
5.

Correlation between improvements in Overactive Bladder Symptom Score and health-related quality of life questionnaires in overactive bladder patients treated with an antimuscarinic drug.

Kubota Y, Kojima Y, Shibata Y, Imura M, Kohri K, Sasaki S.

Neurourol Urodyn. 2011 Sep;30(7):1309-14. doi: 10.1002/nau.21065. Epub 2011 May 10.

PMID:
21560155
6.

[Spanish cultural adaptation and psychometrical validation of the Treatment Benefit Scale (TBS) in the symptomatic treatment of overactive bladder].

Errando-Smet C, Ruiz MA, Villacampa-Aubá F, Arlandis-Guzmán S, Rejas J, Ruiz L, García-Vargas M.

Med Clin (Barc). 2013 Jan 5;140(1):6-13. doi: 10.1016/j.medcli.2011.11.013. Epub 2012 Jan 16. Spanish.

PMID:
22257604
7.

Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine.

Coyne KS, Elinoff V, Gordon DA, Deng DY, Brodsky M, Glasser DB, Jumadilova Z, Carlsson M.

Int J Clin Pract. 2008 Jun;62(6):925-31. doi: 10.1111/j.1742-1241.2008.01778.x.

PMID:
18479285
8.
9.

Should we use the shorter Thai-version quality of life and symptoms questionnaires in women with overactive bladder?

Bunyavejchevin S, Liao L, Lu SH, Choo MS, Rabbani KJ, Havanond P.

J Obstet Gynaecol Res. 2015 Aug;41(8):1260-5. doi: 10.1111/jog.12699. Epub 2015 Jun 16.

PMID:
26081949
10.

Symptom score change and patient versus doctor satisfaction in overactive bladder before and after anti-muscarinic treatment.

Bunyavejchevin S.

J Obstet Gynaecol Res. 2015 Jun;41(6):957-61. doi: 10.1111/jog.12655. Epub 2015 Mar 15.

PMID:
25773663
11.

Therapeutic benefit in patients switching tolterodine to other novel antimuscarinic agents.

Sánchez-Ballester F, Miranda P, Lizarraga I, Rejas J, Arumi D.

Actas Urol Esp. 2014 Apr;38(3):156-63. doi: 10.1016/j.acuro.2013.07.008. Epub 2013 Oct 8. English, Spanish.

PMID:
24119382
12.

Do patient characteristics predict responsiveness to treatment of overactive bladder with antimuscarinic agents?

Herschorn S, Kaplan SA, Sun F, Ntanios F.

Urology. 2014 May;83(5):1023-9. doi: 10.1016/j.urology.2013.12.027. Epub 2014 Feb 26.

PMID:
24582119
13.

Patient satisfaction with the benefits of overactive bladder treatment: exploration of influencing factors and development of a satisfaction assessment instrument.

Zinner N, Kobashi K, Koochaki P, Fix D, Egermark M.

Neurourol Urodyn. 2011 Jan;30(1):62-8. doi: 10.1002/nau.20890. Epub 2010 Sep 21.

PMID:
20860020
14.

The translation and validation of Chinese overactive bladder symptom score for assessing overactive bladder syndrome and response to solifenacin treatment.

Chou EC, Hung MJ, Yen TW, Chuang YC, Meng E, Huang ST, Kuo HC.

J Formos Med Assoc. 2014 Aug;113(8):506-12. doi: 10.1016/j.jfma.2012.07.044. Epub 2012 Oct 16.

15.

Psychometric assessment of female overactive bladder syndrome and antimuscarinics-related effects.

Hsiao SM, Liao SC, Chen CH, Chang TC, Lin HH.

Maturitas. 2014 Dec;79(4):428-34. doi: 10.1016/j.maturitas.2014.08.009. Epub 2014 Sep 3.

PMID:
25238744
16.

A comparison study of two lower urinary tract symptoms screening tools in clinical practice: the B-SAQ and OAB-V8 questionnaires.

Basra RK, Cortes E, Khullar V, Kelleher C.

J Obstet Gynaecol. 2012 Oct;32(7):666-71. doi: 10.3109/01443615.2012.696158.

PMID:
22943714
17.

A prospective randomized trial comparing the use of tolterodine or weighted vaginal cones in women with overactive bladder syndrome.

Yüce T, Dökmeci F, Çetinkaya ŞE.

Eur J Obstet Gynecol Reprod Biol. 2016 Feb;197:91-7. doi: 10.1016/j.ejogrb.2015.11.034. Epub 2015 Dec 2.

PMID:
26720597
18.

Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.

Garely AD, Lucente V, Vapnek J, Smith N.

Ann Pharmacother. 2007 Mar;41(3):391-8. Epub 2007 Mar 6.

PMID:
17341526
19.

[Psychometric validation of the OAB-V8 and OAB-V3 scales for the screening of patients with probable overactive bladder in the Spanish population].

Brenes FJ, Angulo JC, Ochayta D, Rejas J, Arumí D, Cañadas A, Lizarraga I.

Med Clin (Barc). 2014 Dec 23;143(12):521-9. doi: 10.1016/j.medcli.2013.10.032. Epub 2014 Apr 13. Spanish.

PMID:
24725856
20.

Impact of symptom improvement on patients' bother and quality of life in female patients with overactive bladder treated by solifenacin (SET-Q).

Gotoh M, Kobayashi T, Sogabe K.

Int J Urol. 2014 May;21(5):505-11. doi: 10.1111/iju.12355. Epub 2013 Dec 5.

Supplemental Content

Support Center